Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiamusi Luling Pharmaceutical Co., Ltd. is a key manufacturing subsidiary of the Sunflower Pharmaceutical Group (also known as Kuihua Pharmaceutical), located in Jiamusi, Heilongjiang Province, China. The company specializes in the research, development, and large-scale production of Traditional Chinese Medicines (TCM) and chemical pharmaceuticals, with a particular emphasis on pediatric and over-the-counter (OTC) healthcare. Its flagship product, the Luling brand pediatric lung-heat coughing granule, is a market leader in China for treating childhood respiratory conditions. Operating multiple GMP-certified production lines, Jiamusi Luling produces a wide range of dosage forms including granules, tablets, and capsules. The company plays a vital role in the Sunflower Group's broader strategy to dominate the Chinese family medicine market through high-quality, accessible therapeutic solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sunflower Group Jiamusi Luling Pharmaceutical.